|
Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation |
Hislop J, Quayyum Z, Elders A, Fraser C, Jenkinson D, Mowatt G, Sharma P, Vale L, Petty R |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Hislop J, Quayyum Z, Elders A, Fraser C, Jenkinson D, Mowatt G, Sharma P, Vale L, Petty R. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation. Health Technology Assessment 2011; 15(25): 1-178 Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents /administration & Benzamides; Confidence Intervals; Cost-Benefit Analysis; Disease Progression; Gastrointestinal Stromal Tumors /drug therapy /economics /pathology; Humans; Imatinib Mesylate; Incidence; Models, Economic; Piperazines /administration & Pyrimidines /administration & Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome; Uncertainty; United States; dosage /economics /therapeutic use; dosage /economics /therapeutic use; dosage /economics /therapeutic use AccessionNumber 22011001788 Date bibliographic record published 21/12/2011 |
|
|
|